Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 584 participants.
Also called NCT06291376
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 584 participants
- Registry
-
NCT06291376
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hong Kong SAR China, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Saudi Arabia, Slovakia, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06291376. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2026-01-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
- Acronym
- I CAN
- Condition
- Immunoglobulin A Nephropathy
- Condition
- IgAN
- Intervention (Drug)
- Ravulizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct06291376- Content hash
e3ec158a0d356f936d604bbedf77ccc255e6f1de47199e2499e0cbb0f0718cd8